Immix Biopharma is trading at $10.68, down 6.89%, amid a newly priced stock offering.
- The offering covers 11,363,637 shares at $11.00 each and is expected to raise $125 million before expenses. The new issuance may weigh on shares through dilution, though the announcement did not explicitly link it to the decline.
- Separately, the company reported an 89% complete response rate in its NEXICART-2 update, a positive clinical result that may offset some downward pressure.